Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].

Magyar onkologia - 1 Jun 2010

Ostoros Gyula, Döme Balázs, Strausz János, Tímár József

Abstract excerpt

Major advancements have been made in the clinical management of non-small cell lung cancer (NSCLC) in the past decade. This development involved the introduction of pemetrexed and several targeted therapies (bevacizumab, erlotinib, gefitinib) in the first and second line treatments of NSCLC. Novel maintenance therapeutic strategies for NSCLC (erlotinib) and for non-squamous-NSCLC (pemetrexed,...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antibodies, Monoclonal, Humanized
Share to Bevacizumab
Share to Drug Administration Schedule

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Erlotinib Hydrochloride

Share to Gefitinib

Share to Glutamates

Share to Guanine

Share to Pemetrexed

Source

Identifiers

PMID: 20576590
DOI: 10.1556/MOnkol.54.2010.2.8

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Changes in the diagnostic and therapeutic strategies of non-small cell lung cancer].PMID 20576590Read ↗

NCCN Guidelines Insights: Non-Small Cell Lung Cancer, Version 5.2018.Semantic proximity Read ↗

[News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].Semantic proximity Read ↗

[Recent changes in the therapeutic strategy for NSCLC in association with new anti-cancer agents].Semantic proximity Read ↗

[Inhibitors of the EGFR pathway in non small cell lung cancer: what's new in 2007?].Semantic proximity Read ↗

Should we continue to use the term non-small-cell lung cancer?Semantic proximity Read ↗

[Non-small lung cancer, ECCO/ESMO congres 2017].Semantic proximity Read ↗

The International Association for the Study of Lung Cancer Consensus Statement on Optimizing Management of EGFR Mutation-Positive Non-Small Cell Lung Cancer: Status in 2016.Semantic proximity Read ↗

Metastatic non-small cell lung cancer management: novel targets and recent clinical advances.Semantic proximity Read ↗

[Molecular profiling of non-small cell lung cancer].Semantic proximity Read ↗

[Targeted therapies and non-small cell carcinomas : novelties].Semantic proximity Read ↗

[Advances of Molecular Targeted Therapy in EGFR-mutated Squamous Cell Lung Cancer].Semantic proximity Read ↗

[Biomarkers and targeted therapies in non-small cell lung cancer: present and future treatments].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.